文献速递系统性红斑狼疮

阿塔西普在SLE ADDRESS II 2b期长期扩展研究中的安全性与临床活性

Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

ADDRESS II 2b期研究长期扩展(LTE)纳入253例SLE患者,评估阿塔西普长期安全性与疗效;各治疗组TEAE发生率相近(90.4%–93.2%),SRI-4与SRI-6应答在改良意向治疗及高疾病活动人群中得以维持,持续150 mg组较初始安慰剂组重度复发风险降低、首次重度复发时间延长。

要点

  • 阿塔西普150 mg长期治疗SLE安全性可接受,疗效持久。
  • 持续150 mg组较初始安慰剂组首次重度复发风险降低、时间延长。
  • LTE中位主动治疗时长83.8周,各组TEAE发生率相近。

核心结论

  • SLE患者长期使用阿塔西普150 mg安全性可接受,且疗效持久。

研究设计与样本

  • ADDRESS II为24周随机双盲安慰剂对照2b期研究,LTE中阿塔西普组维持原剂量,安慰剂组转为阿塔西普150 mg。
  • 共有253例患者进入LTE:阿塔西普150 mg组88例、75 mg组82例、安慰剂/阿塔西普150 mg组83例。
  • LTE中位主动治疗时长为83.8周,长期安全性为主要终点。

主要发现

  • 各组TEAE发生率相似(90.4%–93.2%)。
  • 严重TEAE发生率在阿塔西普150 mg组为12.5%、75 mg组为14.6%、安慰剂/阿塔西普150 mg组为21.7%。
  • 导致停药的TEAE比例分别为5.7%、4.9%和10.8%。
  • SRI-4与SRI-6应答率在改良意向治疗及HDA人群中得以维持。
  • 持续150 mg组较初始接受安慰剂者首次重度复发风险降低、首次重度复发时间延长。

关键数值与推荐

  • HDA定义为筛选时SLEDAI-2K≥10。
  • LTE中位主动治疗时长83.8周;安慰剂组在LTE中转为阿塔西普150 mg。

临床怎么用

  • 对高疾病活动SLE患者,阿塔西普150 mg长期治疗可作为兼顾安全性与持久疗效的选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Atacicept reduced SLE disease activity in the phase 2b ADDRESS II study, particularly in patients with high disease activity (HDA; SLEDAI-2K ≥10) at screening. We assessed long-term safety and efficacy of atacicept in the long-term extension (LTE) of ADDRESS II. METHODS: In the 24-week, randomized, double-blind, placebo-controlled ADDRESS II study, patients received weekly atacicept (75 or 150 mg) or placebo. Atacicept was continued at the same dose in atacicept-treated patients in the LTE; placebo-treated patients switched to atacicept 150 mg. Long-term safety was the primary endpoint. Secondary endpoints included SLE responder index (SRI)-4 and SRI-6 response rates and flares. RESULTS: In total, 253 patients entered the ADDRESS II LTE; 88 received atacicept 150 mg, 82 atacicept 75 mg and 83 placebo/atacicept 150 mg. Median active treatment duration in the LTE was 83.8 weeks. Frequencies of treatment-emergent adverse events (TEAEs) were similar across groups (90.4-93.2%), and 12.5%, 14.6% and 21.7% of patients in the atacicept 150 mg, atacicept 75 mg and placebo/atacicept 150 mg groups reported serious TEAEs during the treatment period. The proportions of patients with TEAEs leading to discontinuation were 5.7%, 4.9% and 10.8%, respectively. SRI-4 and SRI-6 response rates were maintained with atacicept in the modified intent-to-treat and HDA populations and those on continuous 150 mg had a reduced risk of first severe flare and longer time to first severe flare vs those who initially received placebo. CONCLUSION: Long-term treatment with atacicept 150 mg in SLE patients had an acceptable safety profile, with durable efficacy. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02070978.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wallace DJ, Isenberg DA, Morand EF, et al. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33547784. doi:10.1093/rheumatology/keab115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。